Who are ethopabate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Anti-H1N1v Vaccine, adjuvanted Arepanrix, Fluad alone, active oseltamivir, zanamivir for inhalation, Recombinant influenza vaccines.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ethopabate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

ethopabate — Competitive Intelligence Brief

ethopabate (ethopabate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Other.

marketed Neuraminidase Other Live · refreshed every 30 min

Target snapshot

ethopabate (ethopabate).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ethopabate TARGET	ethopabate		marketed		Neuraminidase
Anti-H1N1v Vaccine	Anti-H1N1v Vaccine	Institut National de la Santé Et de la Recherche Médicale, France	marketed	Inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
adjuvanted Arepanrix	adjuvanted Arepanrix	University of British Columbia	marketed	Adjuvanted inactivated influenza vaccine	H1N1 influenza virus hemagglutinin and neuraminidase antigens
Fluad alone	Fluad alone	Korea University Guro Hospital	marketed	Inactivated influenza vaccine with adjuvant	Influenza virus hemagglutinin and neuraminidase antigens; MF59 acts as immunological adjuvant
active oseltamivir	active oseltamivir	University of Oxford	marketed	Neuraminidase inhibitor	Influenza neuraminidase
zanamivir for inhalation	zanamivir for inhalation	University of Oxford	marketed	Neuraminidase inhibitor	Influenza neuraminidase
Recombinant influenza vaccines	Recombinant influenza vaccines	Henry M. Jackson Foundation for the Advancement of Military Medicine	marketed	Vaccine	Influenza hemagglutinin (HA) and neuraminidase (NA) antigens

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ethopabate — Competitive Intelligence Brief. https://druglandscape.com/ci/ethopabate. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab